8-K: Biote Q2 2025 Results: Profit Up, Revenue Guidance Cut

Biote Corp. reported a significant increase in net income and Adjusted EBITDA for Q2 2025, driven by strong dietary supplement sales and gross margin expansion, despite a slight revenue decrease and a downward revision of full-year 2025 guidance.

Summary

• Total revenue for Q2 2025 was $48.9 million, a slight decrease from $49.2 million in the prior year period.
• Gross profit margin improved to 71.6% in Q2 2025, up from 68.8% in the prior year.
• Net income for Q2 2025 was $3.9 million, a significant improvement from a net loss of $(10.4) million in the prior year period.
• Diluted earnings per share attributable to biote Corp. stockholders was $0.10 for Q2 2025, compared to a diluted loss per share of $(0.21) in the prior year.
• Adjusted EBITDA increased 19.1% year-over-year to $15.2 million in Q2 2025, with an Adjusted EBITDA margin of 31.1%.
• Dietary supplement revenue increased by 30.4% year-over-year, while procedure revenue decreased by 8.4%.
• The company initiated an organizational restructuring in early May 2025.
• Fiscal 2025 revenue guidance was adjusted downwards to be greater than $190 million, from the previously disclosed range of $202-$208 million.
• Fiscal 2025 Adjusted EBITDA guidance was revised downwards to be greater than $50 million, from the previously disclosed range of $59-$64 million.
• 2025 Procedure revenue is now expected to decrease at a high single-digit percentage rate, a revision from the prior forecast of 2-4% growth.
• 2025 Dietary supplements revenue is now expected to grow at a mid-teens percentage rate, revised from the prior forecast of approximately 5-10% growth.

Sentiment

Score: 5

Explanation: While Q2 results show improved profitability (net income, Adjusted EBITDA) and strong dietary supplement sales, the significant downward revision of full-year revenue and Adjusted EBITDA guidance, coupled with a projected decline in procedure revenue, indicates underlying challenges and a more cautious outlook. The restructuring is a positive step but its impact is yet to be fully realized.

Positives

• Net income significantly improved to $3.9 million in Q2 2025, compared to a net loss of $(10.4) million in the prior year period.
• Diluted earnings per share was $0.10 in Q2 2025, a positive shift from a loss of $(0.21) in the prior year.
• Adjusted EBITDA increased by 19.1% to $15.2 million, demonstrating improved operational efficiency.
• Adjusted EBITDA margin expanded to 31.1% from 25.9% in the prior year quarter.
• Gross profit margin improved to 71.6% from 68.8%, primarily due to vertical integration of the 503B manufacturing facility and effective cost management.
• Operating income increased by 72.7% to $10.8 million due to higher gross profit and lower operating expenses.
• Dietary supplement revenue showed strong growth, increasing by 30.4% year-over-year.
• The company maintains strong liquidity and intends to continue investing in its value proposition to gain and retain practitioners.
• An organizational restructuring was initiated to strengthen the business and position it for increased and sustainable profitable growth.

Negatives

• Total revenue decreased slightly to $48.9 million in Q2 2025 from $49.2 million in the prior year period.
• Procedure revenue decreased by 8.4% year-over-year.
• Fiscal 2025 revenue guidance was adjusted downwards to greater than $190 million from a previous range of $202-$208 million.
• Fiscal 2025 Adjusted EBITDA guidance was revised downwards to greater than $50 million from a previous range of $59-$64 million.
• The forecast for 2025 procedure revenue growth was significantly revised from 2-4% growth to a high single-digit percentage decrease.
• The organizational restructuring involved 'difficult actions' and is expected to take time before its positive impact is fully realized.

Risks

• Anticipated benefits and successful execution of the organizational restructuring may not be fully realized.
• The success of dietary supplements in attaining significant market acceptance among clinics, practitioners, and their patients is uncertain.
• Customers' reliance on certain third parties to support the manufacturing of bio-identical hormones for prescribers poses a risk.
• Sensitivity to regulatory, economic, environmental, and competitive conditions in certain geographic regions could adversely affect operations.
• The ability to increase the use by practitioners and clinics of the Biote Method at the anticipated rate or at all is not guaranteed.
• The company faces significant competition in its industry.
• The impact of strategic acquisitions and the implementation of growth strategies may not yield expected results.
• The company has a limited operating history, which may make it difficult to evaluate its future prospects.
• The ability to protect intellectual property is crucial for the business.
• The industry is subject to heavy regulatory oversight, and changes in applicable laws or regulations could be detrimental.
• Changes to international tariffs, U.S. trade policy, or similar government actions could negatively impact the business.
• Geopolitical tensions could affect operations.
• The inability to profitably expand in existing markets and into new markets poses a challenge.
• The company may be adversely impacted by other economic, business, and/or competitive factors, including the impact of hurricane and other natural disasters.
• Future exchange and interest rates could negatively affect financial performance.

Future Outlook

Biote adjusted its fiscal 2025 revenue guidance to be greater than $190 million and Adjusted EBITDA guidance to be greater than $50 million, reflecting the impacts of ongoing commercial organization reorganization. Procedure revenue is now expected to decrease at a high single-digit rate, while dietary supplements revenue is expected to grow at a mid-teens rate. The company plans to continue investing in its value proposition to gain and retain practitioners and remains committed to transforming healthy aging, confident in achieving its vision and building long-term value for all stakeholders.

Management Comments

• "Consistent with our action plan to drive structural and cultural change, Biote initiated an organizational restructuring in early May designed to strengthen our business and position us for increased and sustainable profitable growth in the years ahead."
• "While many difficult actions were taken, I am pleased with the initial progress we have already achieved, which has included new leadership, an expansion of corporate talent and an upgraded sales compensation structure that I believe will enable us to enhance productivity and drive long-term success."
• "As we move forward, we remain focused on advancing our key strategic priorities: accelerating new providers, maximizing value from top tier clinics, and strengthening our commercial organization."
• "In just a few months, Biote has achieved meaningful progress in reorganizing our commercial organization and aligning on the strategic priorities that I am confident will drive a higher level of performance and growth."
• "Given the time it will take for our changes to begin to have a positive impact, we are adjusting our fiscal 2025 revenue guidance to be greater than $190 million, as compared to the previously disclosed range of $202-$208 million, and revising our fiscal 2025 Adjusted EBITDA guidance to be greater than $50 million, as compared to the previously disclosed range of $59-$64 million."
• "The restructuring actions we are taking represent decisive steps forward for Biote, and we are executing with focus and conviction to achieve our strategic goals."
• "Our liquidity remains strong and we intend to continue to invest in our value proposition to gain and retain practitioners."
• "Biote remains committed to advancing patient health by transforming healthy aging, and I am confident that we are on the right path to achieve our vision while building long-term value for all stakeholders."

Industry Context

Biote operates in the preventive healthcare sector, specializing in personalized hormone optimization and therapeutic wellness solutions. The reported growth in dietary supplements revenue, contrasted with a decline in procedure revenue, suggests a potential shift in market demand or strategic focus within the wellness industry. The ongoing organizational restructuring indicates the company's efforts to adapt to market dynamics and strengthen its competitive position in a sector focused on healthy aging and patient-centric care.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess performance against global benchmarks.

Legal Proceedings

• Ongoing legal expenses to defend the company against claims asserted by its former owner.
• Other litigation expenses not related to the company's ongoing business.
• Legal settlement gains or losses and related legal expenses.

Stakeholder Impact

• Shareholders: Potential for long-term value creation through restructuring, but short-term uncertainty due to revised guidance. Improved profitability in Q2 is a positive.
• Employees: Impacted by workforce reduction as part of the organizational restructuring.
• Customers (Practitioners/Clinics): The company intends to continue investing in its value proposition to gain and retain practitioners.
• Patients: The company remains committed to advancing patient health by transforming healthy aging through its solutions.

Next Steps

• Continue reorganizing the commercial organization.
• Advance key strategic priorities: accelerating new providers, maximizing value from top tier clinics, and strengthening the commercial organization.
• Continue to invest in the value proposition to gain and retain practitioners.
• Host a conference call on August 6, 2025, at 5:00 p.m. ET to review results and provide a business update.

Key Dates

Recommendation

While Biote demonstrated improved profitability in Q2 2025 with positive net income and Adjusted EBITDA growth, driven by strong dietary supplement sales and margin expansion, the significant downward revision of full-year revenue and Adjusted EBITDA guidance, coupled with an expected decline in procedure revenue, introduces considerable uncertainty. The ongoing organizational restructuring, while necessary for long-term health, implies short-term disruption. Investors should hold to observe the effectiveness of the restructuring and whether the company can stabilize procedure revenue and achieve its revised guidance. The strong liquidity is a positive, but the revised outlook warrants caution.

Keywords

Biote, BTMD, hormone optimization, preventive healthcare, dietary supplements, financial results, Q2 2025, earnings, Adjusted EBITDA, revenue guidance, corporate restructuring, Nasdaq